Safrole can undergo many forms of metabolism. The two major routes are the oxidation of the
allyl side chain and the oxidation of the methylenedioxy group. The oxidation of the allyl side chain is mediated by a
cytochrome P450 complex, which will transform safrole into 1′-hydroxysafrole. The newly formed 1′-hydroxysafrole will undergo a phase II
drug metabolism reaction with a
sulfotransferase enzyme to create 1′-sulfoxysafrole, which can cause
DNA adducts. A different oxidation pathway of the allyl side chain can form
safrole epoxide. So far, this has only been found in rats and guinea pigs. The formed epoxide is a small metabolite due to the slow formation and further metabolism of the compound. An
epoxide hydratase enzyme will act on the epoxide to form dihydrodiol, which can be secreted in urine. The metabolism of safrole through the oxidation of the methylenedioxy proceeds via the cleavage of the methylenedioxy group. This results in two major metabolites:
allylcatechol and its isomer,
propenylcatechol.
Eugenol is a minor metabolite of safrole in humans, mice, and rats. The intact allyl side chain of allylcatechol may then be oxidized to yield 2′,3′-epoxypropylcatechol. This can serve as a substrate for an epoxide hydratase enzyme, and will hydrate the 2′,3′-epoxypropylcatechol to 2′,3′-dihydroxypropylcatechol. This new compound can be oxidized to form
propionic acid (PPA), The epoxide of allylcatechol may also be generated from the cleavage of the methylenedioxy group of the safrole epoxide. The cleavage of the methylenedioxy ring and the metabolism of the allyl group involve hepatic microsomal mixed-function oxidases. ==Toxicity==